Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a 6-month double-blind international Phase III study in 792 patients, significantly more patients receiving cilansetron reported
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury